Skip to main content

Table 1 Clinical data and cerebrospinal fluid (CSF) findings in Parkinson’s disease (PD) patients and controls

From: Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease

  CTRL IND PD 1-2 PD 2.5-4
No. of patients 47 11 46 27
Age in years 60.4 ± 10.9 (45.0 to 83.0) 59.2 ± 9.0 (45.0 to 75.0) 60.3 ± 9.2 (44.0 to 77.0) 63.9 ± 10.1 (49.0 to 83.0)
Disease duration, months - - 25.8 ± 15.1 54.0 ± 41.7
UPDRS III score - - 19.0 ± 5.6 38.0 ± 10.6
H&Y stage - - 1.6 ± 0.4 3.0 ± 0.5
PD medications - - None: 65.2% None: 7.4%
    DA: 19.6% DA: 22.2%
    LD: 4.3% LD: 33.3%
    LD + DA: 10.9% LD + DA: 37.1%
Motor fluctuations - - 7/46 17/27
Albumin ratio (× 10-3) 5.2 (2.3 to 13.1) 5.8 (3.4 to 8.1) 5.6 (2.6 to 16.2) 8.2 (3.0 to 21.2)
IgG ratio (× 10-3) 2.7 (1.1 to 6.9) 2.8 (1.1 to 4.0) 2.7 (1.1 to 9.5) 3.9 (1.6 to 10.4)
  1. The top half of the table shows clinical data expressed as mean ± SD (minimum to maximum). The lower half shows biochemical values expressed as median (minimum to maximum).
  2. CTRL = control group of healthy subjects; DA = dopamine agonists; H&Y = Hoehn-Yahr; IND = independent group with no neurological disease; LD = levodopa; PD 1–2 = Parkinson’s disease patients with H&Y stage ranging from 1 to 2; PD 2.5-4 = Parkinson’s disease patients with H&Y stage ranging from 2.5 to 4; UPDRS = Unified Parkinson’s Disease Rating Scale.